The usual Tudorza Pressair dosage for COPD is 1 inhalation twice daily. Specific dosages may vary depending on your individual symptoms and other medications you take. It’s important to use the ...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Circassia Pharmaceuticals Inc. (“Circassia” or “the Company”), today announced that the US Food and Drug Administration has approved DUAKLIR® PRESSAIR® (aclidinium ...
The U.S. Food and Drug Administration today approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm (narrowing of the airways in the lung) associated ...
Tudorza Pressair Labeling Updated With Data Related to COPD Patients With Cardiovascular Comorbidity
The Food and Drug Administration (FDA) has approved the inclusion of new data from the ASCENT trial in the prescribing information for Tudorza Pressair (aclidinium bromide inhalation powder; Circassia ...
The FDA on Monday approved Tudorza™ Pressair™ (aclidinium bromide inhalation powder) for long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), ...
TUDORZA PRESSAIR (aclidinium bromide) 400mcg inhalation powder by Forest Laboratories Forest Laboratories and Almirall announced that the FDA has approved Tudorza Pressair (aclidinium bromide ...
Forest Laboratories and Almirall Announce FDA Approval of Tudorza(TM) Pressair(TM) for the Long-Term Maintenance Treatment of COPD NEW YORK & BARCELONA, Spain, Jul 23, 2012 -- Forest Laboratories, Inc ...
Forest Laboratories, Inc.Frank J. Murdolo, 212-224-6714Vice President - Investor Relationsor Media information:enquiries:KetchumSonia San Segundo, 00-34-91-788-32-00orInvestor Relations:AlmirallJordi ...
Forest Laboratories and Almirall announce commercial availability of Tudorza™ Pressair™ in US pharma
NEW YORK & BARCELONA, Spain--(BUSINESS WIRE)-- Forest Laboratories, Inc. (NYS: FRX) and Almirall, S.A. (ALM:MC) announced today that Tudorza™ Pressair™ (aclidinium bromide inhalation powder) 400mcg is ...
Almirall, S.A. (ALM.MC) and Forest Laboratories, Inc. (NYSE:FRX) announced that the U.S. Food and Drug Administration (FDA) has approved Tudorza™ Pressair™ (aclidinium bromide inhalation powder) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results